Literature DB >> 32366927

Effects of chronic type 5 phosphodiesterase inhibition on penile microvascular reactivity in hypertensive patients with erectile dysfunction: a randomized crossover placebo-controlled trial.

Valéria Verri1, Alessandro R Nascimento1, Andrea A Brandao2, Eduardo Tibirica3.   

Abstract

This randomized crossover and placebo-controlled trial evaluated the effects of daily use of sildenafil citrate (SIL, 1-month 50 mg twice daily) on penile and systemic endothelial microvascular function in hypertensive patients presenting with erectile dysfunction. The effects of SIL on arterial pressure were evaluated using ambulatory blood pressure monitoring (ABPM). Fifty patients diagnosed with primary arterial hypertension and erectile dysfunction (aged 57.4 ± 5.6 years), recruited in a tertiary public hospital, were treated with SIL (50 mg twice daily) or placebo (PLA) for two 30-day periods with a 30-day washout between them. Laser speckle contrast imaging coupled with acetylcholine skin iontophoresis was used to evaluate penile and systemic (forearm) cutaneous microvascular reactivity. SIL treatment increased penile basal microvascular flow (P = 0.002) and maximal endothelial-dependent peak response to skin iontophoresis of acetylcholine (ACh, P = 0.006). The area under the curve of microvascular vasodilation induced by ACh was also significantly increased (P = 0.02). Lastly, SIL treatment did not modify systemic microvascular reactivity. Twenty-four-hour ABPM (P = 0.0002) and daytime (P = 0.002) and nighttime (P = 0.001) mean diastolic blood pressure values were significantly reduced after SIL treatment. The scores of the Simplified International Index of Erectile Function (P < 0.0001) and the number of patients with positive responses to Sexual Encounter Profile question 3 (P < 0.0001) also increased after SIL treatment. Penile endothelium-dependent microvascular reactivity improved after continuous use of sildenafil in hypertensive patients with erectile dysfunction; the treatment also reduced blood pressure, suggesting that, in addition to improving erectile function, daily use of sildenafil could improve blood pressure control.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32366927     DOI: 10.1038/s41371-020-0343-3

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  39 in total

1.  Erectile dysfunction and subsequent cardiovascular disease.

Authors:  Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; Jeffrey L Probstfield; Carol M Moinpour; Charles A Coltman
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

2.  Hypertension is associated with severe erectile dysfunction.

Authors:  M Burchardt; T Burchardt; L Baer; A J Kiss; R V Pawar; A Shabsigh; A de la Taille; O R Hayek; R Shabsigh
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

Review 3.  The epidemiology of erectile dysfunction and its risk factors.

Authors:  A Bortolotti; F Parazzini; E Colli; M Landoni
Journal:  Int J Androl       Date:  1997-12

4.  Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group.

Authors:  R A Kloner; M Brown; L M Prisant; M Collins
Journal:  Am J Hypertens       Date:  2001-01       Impact factor: 2.689

5.  Erectile dysfunction and sildenafil citrate and cardiologists.

Authors:  R A Kloner; J P Jarow
Journal:  Am J Cardiol       Date:  1999-02-15       Impact factor: 2.778

Review 6.  Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?

Authors:  Vivian Fonseca; Ali Jawa
Journal:  Am J Cardiol       Date:  2005-12-01       Impact factor: 2.778

Review 7.  Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator.

Authors:  H Solomon; J W Man; G Jackson
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

Review 8.  Sildenafil is well tolerated by erectile dysfunction patients taking antihypertensive medications, including those on multidrug regimens.

Authors:  Marko Böhm; Martin Burkart; Gert Baumann
Journal:  Curr Drug Saf       Date:  2007-01

Review 9.  Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

Authors:  Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

10.  The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.

Authors:  Ajay Nehra; Graham Jackson; Martin Miner; Kevin L Billups; Arthur L Burnett; Jacques Buvat; Culley C Carson; Glenn R Cunningham; Peter Ganz; Irwin Goldstein; Andre T Guay; Geoff Hackett; Robert A Kloner; John Kostis; Piero Montorsi; Melinda Ramsey; Raymond Rosen; Richard Sadovsky; Allen D Seftel; Ridwan Shabsigh; Charalambos Vlachopoulos; Frederick C W Wu
Journal:  Mayo Clin Proc       Date:  2012-08       Impact factor: 7.616

View more
  1 in total

Review 1.  Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: Impact on Disease Severity.

Authors:  Andrea De Lorenzo; Vanessa Estato; Hugo C Castro-Faria-Neto; Eduardo Tibirica
Journal:  J Inflamm Res       Date:  2021-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.